Interferon-α may help prevent molecular relapse of chronic myeloid leukemia after the discontinuation of tyrosine kinase inhibitors

BACKGROUND: Currently, the goal of chronic myeloid leukemia (CML) treatment is normal survival and good quality of life without life-long treatment, namely, “treatment-free remission” (TFR). At present, approximately only 50% of patients with CML with a deep molecular response are able to discontinu...

Descripción completa

Detalles Bibliográficos
Autores principales: Jun, Kong, Ya-zhen, Qin, Xiao-su, Zhao, Hong-Xia, Shi, Yue-Yun, Lai, Kai-yan, Liu, Xiao-jun, Huang, Hao, Jiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841675/
https://www.ncbi.nlm.nih.gov/pubmed/33613929
http://dx.doi.org/10.1177/2040620720986643

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841675/
https://www.ncbi.nlm.nih.gov/pubmed/33613929
http://dx.doi.org/10.1177/2040620720986643

Ejemplares similares